Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 13/20 | 0.63 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5037008 | 1.00 | ADRB2 (0.63) | ADRB2TRPV1MEN1NPC1RAB9A | |
| SCHEMBL5037585 | 0.93 | ADRB2 (0.58) | ADRB2TRPV1 | |
| SCHEMBL5037588 | 0.93 | ADRB2 (0.58) | ADRB2TRPV1 | |
| SCHEMBL5043938 | 0.90 | ADRB2 (0.59) | ADRB2TRPV1ADRA1DADRA1AADRA1B | |
| SCHEMBL5043935 | 0.90 | ADRB2 (0.59) | ADRB2TRPV1ADRA1DADRA1AADRA1B | |
| SCHEMBL14204685 | 0.88 | ADRB2 (0.46) | ADRB2TRPV1ADRA1DADRA1AADRA1B | |
| SCHEMBL5034327 | 0.88 | ADRB2 (0.47) | ADRB2TRPV1ADRA1DADRA1AADRA1B | |
| SCHEMBL5034329 | 0.88 | ADRB2 (0.47) | ADRB2TRPV1ADRA1DADRA1AADRA1B | |
| SCHEMBL14230507 | 0.87 | ADRB2 (0.81) | ADRB2 | |
| SCHEMBL5041942 | 0.85 | ADRB2 (0.45) | ADRB2TRPV1ADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351742-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC. (US) | 2008-04-01 | — | — | US | disclosed |
| EP-1708992-B1 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER LTD (GB) | 2007-08-08 | — | — | EP | disclosed |
| EP-1708992-A1 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | Pfizer Limited (GB) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005080324-A1 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER LIMITED (GB) | 2005-09-01 | — | — | WO | disclosed |
| US-20050171147-A1 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC. | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171147-A1 | Sulfonamide derivatives for the treatment of diseases | SULT2A1, STS, SULT1A1 | ADRB2 2148/4885TRPV1 88/4885MEN1 3159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.